These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34185508)

  • 1. Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.
    Jäger S; Wagner TR; Rasche N; Kolmar H; Hecht S; Schröter C
    Bioconjug Chem; 2021 Aug; 32(8):1699-1710. PubMed ID: 34185508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing.
    Jäger S; Dickgiesser S; Tonillo J; Hecht S; Kolmar H; Schröter C
    Biol Chem; 2022 Apr; 403(5-6):525-534. PubMed ID: 34535048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fcab-HER2 Interaction: a Ménage à Trois. Lessons from X-Ray and Solution Studies.
    Lobner E; Humm AS; Göritzer K; Mlynek G; Puchinger MG; Hasenhindl C; Rüker F; Traxlmayr MW; Djinović-Carugo K; Obinger C
    Structure; 2017 Jun; 25(6):878-889.e5. PubMed ID: 28528777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.
    Woisetschläger M; Antes B; Borrowdale R; Wiederkum S; Kainer M; Steinkellner H; Wozniak-Knopp G; Moulder K; Rüker F; Mudde GC
    Biotechnol J; 2014 Jun; 9(6):844-51. PubMed ID: 24806546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered IgG1-Fc--one fragment to bind them all.
    Lobner E; Traxlmayr MW; Obinger C; Hasenhindl C
    Immunol Rev; 2016 Mar; 270(1):113-31. PubMed ID: 26864108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.
    Traxlmayr MW; Lobner E; Antes B; Kainer M; Wiederkum S; Hasenhindl C; Stadlmayr G; Rüker F; Woisetschläger M; Moulder K; Obinger C
    Protein Eng Des Sel; 2013 Apr; 26(4):255-65. PubMed ID: 23267121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.
    Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Woisetschläger M; Sun H; Rüker F
    Protein Eng Des Sel; 2017 Sep; 30(9):657-671. PubMed ID: 28981753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution.
    Traxlmayr MW; Lobner E; Hasenhindl C; Stadlmayr G; Oostenbrink C; Rüker F; Obinger C
    Biotechnol J; 2014 Aug; 9(8):1013-22. PubMed ID: 24964247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yeast Surface Display and Cell Sorting of Antigen-Binding Fc Fragments.
    Sádio F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
    Methods Mol Biol; 2019; 1923():287-308. PubMed ID: 30737746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties.
    Wozniak-Knopp G; Bartl S; Bauer A; Mostageer M; Woisetschläger M; Antes B; Ettl K; Kainer M; Weberhofer G; Wiederkum S; Himmler G; Mudde GC; Rüker F
    Protein Eng Des Sel; 2010 Apr; 23(4):289-97. PubMed ID: 20150180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-faced Fcab prevents polymerization with VEGF and reveals thermodynamics and the 2.15 Å crystal structure of the complex.
    Lobner E; Humm AS; Mlynek G; Kubinger K; Kitzmüller M; Traxlmayr MW; Djinović-Carugo K; Obinger C
    MAbs; 2017 Oct; 9(7):1088-1104. PubMed ID: 28816592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments.
    Jez J; Antes B; Castilho A; Kainer M; Wiederkum S; Grass J; Rüker F; Woisetschläger M; Steinkellner H
    J Biol Chem; 2012 Jul; 287(29):24313-9. PubMed ID: 22589538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and testing of engineered multimeric Fabs of trastuzumab.
    Selis F; Sandomenico A; Cantile M; Sanna R; Calvanese L; Falcigno L; Dell'Omo P; Esperti A; De Falco S; Focà A; Caporale A; Iaccarino E; Truppo E; Scaramuzza S; Tonon G; Ruvo M
    Int J Biol Macromol; 2020 Dec; 164():4516-4531. PubMed ID: 32941911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
    de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
    MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment.
    Bryden F; Maruani A; Savoie H; Chudasama V; Smith ME; Caddick S; Boyle RW
    Bioconjug Chem; 2014 Mar; 25(3):611-7. PubMed ID: 24564170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the serum stability of site-specific antibody conjugates with sulfone linkers.
    Patterson JT; Asano S; Li X; Rader C; Barbas CF
    Bioconjug Chem; 2014 Aug; 25(8):1402-7. PubMed ID: 25099687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.